Document
IPR2021-00816, No. 2082-213 Exhibit - Exhibit 2082 PUBLIC REDACTED VERSION (P.T.A.B. Nov. 19, 2021)
Cite Document
IPR2021-00816, No. 2082-213 Exhibit - Exhibit 2082 PUBLIC REDACTED VERSION (P.T.A.B. Nov. 19, 2021)
+ More Snippets
Document
IPR2021-00816, No. 2075-206 Exhibit - Exhibit 2075 PUBLIC REDACTED VERSION (P.T.A.B. Nov. 19, 2021)
Cite Document
IPR2021-00816, No. 2075-206 Exhibit - Exhibit 2075 PUBLIC REDACTED VERSION (P.T.A.B. Nov. 19, 2021)
+ More Snippets
Document
IPR2021-00816, No. 1235-628 Exhibit - ���Highlights of Prescribing Information,��� Eylea, FDA, revised August 2019 (P.T.A.B. Apr. 15, 2022)
Cite Document
IPR2021-00816, No. 1235-628 Exhibit - ���Highlights of Prescribing Information,��� Eylea, FDA, revised August 2019 (P.T.A.B. Apr. 15, 2022)
+ More Snippets
Document
IPR2021-00816, No. 1166-599 Exhibit - Accessing Inaccessible Interfaces In Situ Approaches to Materials Tribology, W G Sawyer K J Wahl, Guest Editors MRS Bulletin 33 2008 1145 1189 (P.T....
Cite Document
IPR2021-00816, No. 1166-599 Exhibit - Accessing Inaccessible Interfaces In Situ Approaches to Materials Tribology, W G Sawyer K J Wahl, Guest Editors MRS Bulletin 33 2008 1145 1189 (P.T.A.B. Apr. 15,
+ More Snippets
Document
IPR2021-00816, No. 2203-460 Exhibit - Ex 2203 Declaration of Michael J Miller Public Redacted Version (P.T.A.B. Jan. 19, 2022)
Cite Document
IPR2021-00816, No. 2203-460 Exhibit - Ex 2203 Declaration of Michael J Miller Public Redacted Version (P.T.A.B. Jan. 19, 2022)
+ More Snippets
Document
IPR2021-00816, No. 2345-684 Exhibit - Deposition Transcript of Szilard Kiss, MD, Vol 2 May 13, 2022 Redacted Version (P.T.A.B. May. 26, 2022)
Cite Document
IPR2021-00816, No. 2345-684 Exhibit - Deposition Transcript of Szilard Kiss, MD, Vol 2 May 13, 2022 Redacted Version (P.T.A.B. May. 26, 2022)
+ More Snippets
Document
IPR2021-00816, No. 1187-620 Exhibit - Callan Navitsky, The Regulation of Compounding Pharmacies, Retina Today, NovemberDecember 2012 (P.T.A.B. Apr. 15, 2022)
Cite Document
IPR2021-00816, No. 1187-620 Exhibit - Callan Navitsky, The Regulation of Compounding Pharmacies, Retina Today, NovemberDecember 2012 (P.T.A.B. Apr. 15, 2022)
+ More Snippets
Document
IPR2021-00816, No. 1095-225 Exhibit - Declaration of Petra Scamborova (P.T.A.B. Dec. 22, 2021)
Cite Document
IPR2021-00816, No. 1095-225 Exhibit - Declaration of Petra Scamborova (P.T.A.B. Dec. 22, 2021)
+ More Snippets
Document
IPR2021-00816, No. 2096-192 Exhibit - Exhibit 2096 (P.T.A.B. Aug. 27, 2021)
Cite Document
IPR2021-00816, No. 2096-192 Exhibit - Exhibit 2096 (P.T.A.B. Aug. 27, 2021)
+ More Snippets
Document
IPR2021-00816, No. 1090-188 Exhibit - Text Minute Entry re Rule 16 Conference held on August 18, 2021, Novartis Pharma AG et al v Regeneron Pharma, Inc, No 120 cv 00690 NDNY Aug 18, 2...
Cite Document
IPR2021-00816, No. 1090-188 Exhibit - Text Minute Entry re Rule 16 Conference held on August 18, 2021, Novartis Pharma AG et al v Regeneron Pharma, Inc, No 120 cv 00690 NDNY Aug 18, 2021 (P.T.A.B. Aug
+ More Snippets
Document
IPR2021-00816, No. 1090-188 Exhibit - Text Minute Entry re Rule 16 Conference held on August 18, 2021, Novartis Pharma AG et al v Regeneron Pharma, Inc, No 120 cv 00690 NDNY Aug 18, 2...
Cite Document
IPR2021-00816, No. 1090-188 Exhibit - Text Minute Entry re Rule 16 Conference held on August 18, 2021, Novartis Pharma AG et al v Regeneron Pharma, Inc, No 120 cv 00690 NDNY Aug 18, 2021 (P.T.A.B. Aug
+ More Snippets
Document
IPR2021-00816, No. 1050-59 Exhibit - IPR2020 1317, Paper No 10, Patent Owner���s Preliminary Response (P.T.A.B. Apr. 16, 2021)
Cite Document
IPR2021-00816, No. 1050-59 Exhibit - IPR2020 1317, Paper No 10, Patent Owner���s Preliminary Response (P.T.A.B. Apr. 16, 2021)
+ More Snippets
Document
IPR2021-00816, No. 1025-34 Exhibit - Lu Liu et al, Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab Effects of Long term Storage and Product M...
Cite Document
IPR2021-00816, No. 1025-34 Exhibit - Lu Liu et al, Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab Effects of Long term Storage and Product Mishandling, 522
+ More Snippets
Document
IPR2021-00816, No. 1056-65 Exhibit - US Food and Drug Administration, Trivaris �� Highlights of the Prescribing Information, May 2008 ���Trivaris label��� (P.T.A.B. Apr. 16, 2021)
Cite Document
IPR2021-00816, No. 1056-65 Exhibit - US Food and Drug Administration, Trivaris �� Highlights of the Prescribing Information, May 2008 ���Trivaris label��� (P.T.A.B. Apr. 16, 2021)
+ More Snippets
Document
IPR2021-00816, No. 1031-40 Exhibit - Declaration of Dr Szilard Kiss under 37 CFR �� 168 (P.T.A.B. Apr. 16, 2021)
Cite Document
IPR2021-00816, No. 1031-40 Exhibit - Declaration of Dr Szilard Kiss under 37 CFR �� 168 (P.T.A.B. Apr. 16, 2021)
+ More Snippets